Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiologists' perspectives on sociocultural and structural factors shaping cardiovascular genetic testing.

medRxiv : the preprint server for health sciences·2026

Same author

Identifying anaphylaxis using weakly-supervised prediction models and natural language processing.

medRxiv : the preprint server for health sciences·2026

Same author

Administrative Burden as a Potential Cause of Financial Hardship and Poor Mental Health in Cancer: A Mixed Methods Study.

JCO oncology practice·2026

Same author

Care Gap: Identifying and Bridging Barriers in Primary Palliative Care.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

The IMPACT-FH Renewal Protocol: Evaluating FH Cascade Testing Implementation in Primary Care through a Pragmatic Trial, Economic Evaluation, and Mixed-Methods Sustainability Assessment.

Public health genomics·2026

Same author

Serious Illness and Health Care Threats to Personal Legacy Goals.

The Permanente journal·2026

Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026

Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026

Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026

Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026

Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026

Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 13, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Implementation of a Traceback Testing Program for Ovarian Cancer: Findings from the FACTS Study.

Nora B Henrikson¹, M Cabell Jonas², Paula R Blasi¹

¹Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Suite 1360, Seattle, WA 98101, USA.

|April 14, 2025

Summary

This summary is machine-generated.

Traceback genetic testing identified cancer risks in 8% of eligible individuals. However, cascade testing for relatives was not achieved in this pilot study, indicating a need for further research.

Keywords:

cancer prevention gynecologic cancer risk reduction ovarian cancer

More Related Videos

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

Characterization and Functional Prediction of Bacteria in Ovarian Tissues

Characterization and Functional Prediction of Bacteria in Ovarian Tissues

Published on: October 23, 2021

Related Experiment Videos

Last Updated: May 13, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

Characterization and Functional Prediction of Bacteria in Ovarian Tissues

Characterization and Functional Prediction of Bacteria in Ovarian Tissues

Published on: October 23, 2021

Area of Science:

Genetics
Oncology
Public Health

Background:

Traceback testing identifies individuals with prior cancer diagnoses who missed current genetic testing.
This approach aims to benefit both patients and their at-risk relatives by uncovering hereditary cancer predispositions.
Previous genetic testing may not have been standard or accessible for all patients with cancer history.

Purpose of the Study:

To evaluate the implementation of a Traceback program in three US health systems.
To assess the reach, fidelity, effectiveness, and acceptability of the Traceback program.
To determine the feasibility and potential benefits of identifying and testing previously untested individuals with cancer history.

Main Methods:

A multisite, nonrandomized pilot implementation study was conducted.
Quantitative and qualitative methods were used to assess program outcomes.
Eligible individuals were identified via administrative data and chart review, followed by outreach and genetic testing.

Main Results:

597 individuals were identified as eligible, with 59% successfully contacted.
133 individuals completed Traceback genetic testing, and 8% received pathogenic or likely pathogenic results.
No relatives underwent cascade testing, despite 90% of positive results indicating its need; 36 individuals received variants of uncertain significance (VUS).

Conclusions:

Traceback programs demonstrated high participant and implementer acceptability and applicability to other genetic screening conditions.
Despite positive genetic results, cascade testing for relatives was not achieved in this pilot.
Further study is warranted to explore the benefits and sustainability of Traceback programs, particularly regarding resource allocation for identifying eligible individuals.